BIAF · bioAffinity Technologies, Inc.
bioAffinity Technologies Inc (BIAF)
What's happening
- BIAF is up 49.09% today, trading at $9.81. — Live quote
- It's trading within 3% of its 52-week low ($4.56). (Finnhub fundamentals)
- Volume today (214,543) is well below its 3-month average of 676,440. (Finnhub fundamentals)
- Last quarter's EPS missed estimates: $-4.74 actual vs. $-2.75 estimated (-72.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-03-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $64.6M | $259.5M | $379.8M | $809.7M | $520.8M |
| P/E | -4.01 | -16.85 | -27.57 | -74.74 | -59.63 |
| Price/Sales | 11.58 | 43.83 | 54.89 | 102.86 | 57.81 |
| Price/Book | 17.14 | 71.16 | 42.66 | -379.03 | 361.80 |
| EV/Revenue | 11.14 | 43.31 | 53.82 | 102.76 | 57.76 |
| ROE | -427.42% | -422.34% | -154.72% | 507.11% | -606.73% |
| ROA | -211.42% | -193.86% | -119.29% | -228.00% | -157.43% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-01; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -27.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -280.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -93.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on BIAF
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.4M | $1.4M | $1.3M | $1.9M | $2.4M | $2.4M | $2.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.3M | -$3.6M | -$2.3M | -$2.5M | -$2.6M | -$2.0M | -$2.1M | -$1.9M |
| Net income | -$3.4M | -$3.6M | -$5.1M | -$4.1M | -$2.7M | -$2.0M | -$2.1M | -$2.0M |
| EPS (diluted) | $-0.64 | $-0.81 | $-4.74 | $-5.07 | $-4.80 | $-4.84 | $-0.19 | $-0.20 |
| EPS (basic) | $-0.64 | $-0.81 | $-4.74 | $-5.07 | $-4.80 | $-4.84 | $-0.19 | $-0.20 |
| Operating margin | -$221 | -$268 | -$159 | -$198 | -$142 | -$84 | -$87 | -$81 |
| Net margin | -$223 | -$269 | -$349 | -$320 | -$144 | -$85 | -$88 | -$82 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | May '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $7.6M | $7.9M | $11.0M | $11.5M | $4.8M | — | $5.5M | $6.5M |
| Total liabilities | $3.9M | $4.3M | $3.7M | $2.6M | $6.9M | — | $4.1M | $3.9M |
| Stockholders' equity | $3.8M | $3.6M | $7.3M | $8.9M | -$2.1M | — | $1.4M | $2.6M |
| Total current assets | $3.9M | $4.3M | $7.6M | $8.6M | $1.7M | — | $1.9M | $2.7M |
| Total current liabilities | $2.7M | $3.2M | $2.9M | $2.4M | $2.6M | — | $3.4M | $3.1M |
| Cash & equivalents | $2.4M | $3.1M | $6.4M | $7.7M | $802.8K | — | $444.7K | $1.1M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Inventory | $82.4K | $77.9K | $53.5K | $35.2K | $44.0K | — | $38.8K | $27.6K |
| Property, plant & equipment | $313.7K | $246.8K | $265.6K | $303.1K | $351.4K | — | $382.4K | $375.4K |
| Goodwill | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | — | $1.4M | $1.4M |
| Intangible assets | $687.6K | $702.2K | $716.8K | $731.4K | $746.0K | — | $760.6K | $775.1K |
| Other non-current assets | $16.7K | $12.8K | $12.8K | $12.8K | $12.8K | — | $19.7K | $19.7K |
| Accounts payable | $969.8K | $836.2K | $761.9K | $940.8K | $1.2M | — | $1.4M | $987.3K |
| Accrued liabilities | $1.4M | $2.0M | $1.7M | $984.5K | $1.0M | — | $1.4M | $1.4M |
| Deferred revenue (current) | $31.1K | $31.1K | $42.4K | $37.9K | $24.4K | — | $24.4K | $24.4K |
| Short-term debt | — | — | — | $260.0K | — | — | — | — |
| Common stock & paid-in capital | $47.5K | $31.5K | $31.5K | $24.3K | $197.2K | $5.8M | $124.8K | $3.6K |
| Retained earnings | -$75.6M | -$72.2M | -$68.6M | -$65.4M | -$60.4M | — | -$56.3M | -$53.6M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.2M | -$3.2M | -$2.6M | -$2.5M | -$2.6M | -$1.6M | -$1.7M | -$1.7M |
| Investing cash flow | -$90.0K | -$5.7K | -$1 | $3.6K | -$13.4K | -$50.8K | -$1 | -$9.4K |
| Financing cash flow | $2.6M | -$118.5K | $1.3M | $9.3M | $3.0M | $1.0M | $2.0M | $1.7M |
| Free cash flow | -$3.3M | -$3.2M | -$2.6M | -$2.5M | -$2.7M | -$1.7M | -$1.7M | -$1.7M |
| Capital expenditures | $90.0K | $5.7K | $1 | -$3.6K | $13.4K | $50.8K | $1 | $9.4K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $784.9K | $14.3K | $66.1K | $67.1K | $211.6K | $326.6K | $234.1K | $185.7K |
| Change in inventory | $4.5K | $24.3K | $18.3K | -$8.7K | $5.2K | $11.2K | $2.2K | -$4.4K |
| Change in accounts payable | $133.6K | $74.3K | -$178.9K | -$229.1K | -$211.7K | $394.3K | $204.4K | -$65.2K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4.8K | — |
| Gross profit | — | — | — | $4.3K | — |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M | -$2.2M |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| EPS (diluted) | $-8.66 | $-22.50 | $-0.91 | $-1.81 | — |
| EPS (basic) | $-8.66 | $-22.50 | $-0.91 | $-1.81 | $-2.36 |
| Operating margin | -$172 | -$96 | -$315 | -$83.5K | — |
| Net margin | -$242 | -$97 | -$313 | -$169.8K | — |
Balance sheet
| Line item | Dec '25 | Sep '25 | May '25 | Dec '24 | Dec '23 |
|---|---|---|---|---|---|
| Total assets | $11.0M | — | — | $6.5M | $8.2M |
| Total liabilities | $3.7M | — | — | $3.9M | $3.4M |
| Stockholders' equity | $7.3M | — | — | $2.6M | $4.9M |
| Total current assets | $7.6M | — | — | $2.7M | $4.0M |
| Total current liabilities | $2.9M | — | — | $3.1M | $2.2M |
| Cash & equivalents | $6.4M | — | — | $1.1M | $2.8M |
| Inventory | $53.5K | — | — | $27.6K | $18.5K |
| Property, plant & equipment | $265.6K | — | — | $375.4K | $458.6K |
| Goodwill | $1.4M | — | — | $1.4M | $1.4M |
| Intangible assets | $716.8K | — | — | $775.1K | $833.5K |
| Other non-current assets | $12.8K | — | — | $19.7K | $16.1K |
| Accounts payable | $761.9K | — | — | $987.3K | $604.8K |
| Accrued liabilities | $1.7M | — | — | $1.4M | $1.1M |
| Deferred revenue (current) | $42.4K | — | — | $24.4K | $33.1K |
| Short-term debt | — | $127.5K | — | — | — |
| Common stock & paid-in capital | $31.5K | — | $5.8M | $3.6K | $65.8K |
| Retained earnings | -$68.6M | — | — | -$53.6M | -$44.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.3M | -$7.3M | -$6.0M | -$4.1M | -$2.0M |
| Investing cash flow | -$60.6K | -$79.1K | -$2.2M | -$220.0K | — |
| Financing cash flow | $14.7M | $5.6M | -$345.0K | $14.3M | $3.3M |
| Free cash flow | -$9.4M | -$7.3M | -$6.1M | -$4.3M | — |
| Capital expenditures | $60.6K | $79.1K | $22.9K | $220.0K | — |
| Share-based compensation | $671.5K | $989.7K | $748.8K | $248.6K | $43.0K |
| Change in inventory | $25.9K | $9.1K | $12.9K | $5.5K | — |
| Change in accounts payable | -$225.4K | $382.5K | -$14.5K | $114.6K | $39.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding BIAF as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-04-03 to 2025-01-10
Recent transactions
- Most recent: Reveles Xavier Trinidad (Chief Operating Officer) — Grant / award of 21,604 shares on 2025-01-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Reveles Xavier Trinidad | Chief Operating Officer | Grant / award | 2025-01-10 | 21,604 |
| GIRGENTI STEVEN | Executive Chairman | Grant / award | 2025-01-10 | 14,814 |
| Zannes Maria | President & CEO | Grant / award | 2025-01-10 | 37,037 |
| Edwards James Michael | VP and CFO | Grant / award | 2025-01-10 | 6,172 |
| Zannes Timothy P | Secretary, EVP, Gen. Counsel | Grant / award | 2025-01-10 | 8,641 |
| DIAMOND STUART | Director | Grant / award | 2024-07-01 | 33,784 |
| Anderson Robert A. | Director | Grant / award | 2024-07-01 | 33,784 |
| Joyce Roby | Director | Grant / award | 2024-07-01 | 33,784 |
| Platt Jamie | Director | Grant / award | 2024-07-01 | 33,784 |
| KNIGHT PETER S | Director | Grant / award | 2024-07-01 | 33,784 |
| Rubin Gary D | Director | Grant / award | 2024-07-01 | 33,784 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-01-10 | Reveles Xavier Trinidad | Chief Operating Officer | Grant / award | 21,604 | $0.00 |
| 2025-01-10 | GIRGENTI STEVEN | Executive Chairman | Grant / award | 14,814 | $0.00 |
| 2025-01-10 | Zannes Maria | President & CEO | Grant / award | 37,037 | $0.00 |
| 2025-01-10 | Edwards James Michael | VP and CFO | Grant / award | 6,172 | $0.00 |
| 2025-01-10 | Zannes Timothy P | Secretary, EVP, Gen. Counsel | Grant / award | 8,641 | $0.00 |
| 2024-11-05 | Edwards James Michael | VP and CFO | Grant / award | 100,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:44 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-01 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-20 | 8-K | 2026-08-20 | View on SEC.gov → |
| 2026-08-18 | 8-K | 2026-08-18 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-30 | View on SEC.gov → |
| 2026-07-27 | 8-K | 2026-07-27 | View on SEC.gov → |
| 2026-07-22 | 8-K | 2026-07-22 | View on SEC.gov → |
| 2026-07-07 | 8-K | 2026-07-07 | View on SEC.gov → |
| 2026-06-30 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-06-18 | 8-K | 2026-06-16 | View on SEC.gov → |
Recent news
Headlines about BIAF (bioAffinity Technologies, Inc.). Links open the publisher — we don’t host full articles.
-
BIAF Stock Rockets As CyPath Lung Growth Collides With Delisting Risk
StocksToTrade · 2026-09-03 -
Why is bioAffinity Technologies stock surging today?
Investing.com · 2026-09-03 -
What's going on in today's session
ChartMill · 2026-09-02 -
bioAffinity Technologies Surges as CyPath Lung Expands Into Cancer Recurrence Monitoring
finance.biggo.com · 2026-09-02 -
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 2026-09-02 -
Here are the top movers in Wednesday's session.
ChartMill · 2026-09-02 -
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 2026-09-02 -
BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
Benzinga · 2026-09-02
No headlines in this category right now — try “All”.